journal article·2018-09-26

Hyaluronan Reduces Cationic Liposome-Induced Toxicity and Enhances the Antitumor Effect of Targeted Gene Delivery in Mice

Yanping Qian, Xiao Liang, Jingyun Yang, Chengjian Zhao, Wen Nie, Li Liu, Tao Yi, Yu Jiang, Jia Geng, Xia Zhao, Xiawei Wei

ACS Applied Materials & Interfaces· Volume 10· Issue 38
Publisher page

Abstract

Cationic nanocarriers are reported to induce cell necrosis, especially in the lungs upon systemic administration. The release of damage-associated molecular patterns, such as mitochondrial DNA from the injured cell may result in the inflammatory toxicity of the nanocarrier, which has largely limited its clinical application. Partial blocking of the surface charge of cationic nanocarriers might improve their safety. As hyaluronan (HA) is an anionic polysaccharide that is widely used for specific binding to CD44 to improve the cellular uptake efficiency in tumor-targeting therapy, in this study, we modified cationic liposomes (LP) with the negatively charged HA at a mass ratio of 10% to prepare targeted HA-modified cationic liposomes (HALP). Cationic liposomes modified with hyaluronan showed significantly less cytotoxicity due to the blockage of their surface charge than the unmodified liposomes. In addition, HA modification helped to reduce cell necrosis in lung tissue and reduced the amount of mitochondria subsequently released, which alleviated pulmonary inflammation in mice. HA-modified liposomes also improved the survival of mice injected with a fatal dose of HALP compared with mice injected with cationic LP. In addition, both serological biochemical analysis and histological examination proved that a liposome modified with HA is a safer carrier for systemic administration than an unmodified liposome. Furthermore, HALP/survivin exhibited an enhanced antitumor effect by inhibiting tumor growth and promoting tumor cell apoptosis compared with the unmodified LP group. In conclusion, compared to the properties of cationic liposomes, liposomes modified with 10% HA (HALP) might be gene vectors with lower toxicity and higher tumor targeting efficiency.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Immunotherapy and Immune Responses · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Gynecology and Obstetrics, Key Laboratory of Obstetrics & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, West China Second Hospital, Sichuan University, Chengdu 610041, P. R. China

Laboratory of Aging Research and Nanotoxicology, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan 610041, P. R. China

Funding

Ministry of Science and Technology of the People's Republic of China · National Natural Science Foundation of China

References (49)

Show source-provided references
1. 10.1038/nmat378810.1038/nmat3788 ↗
2. 10.1021/acsnano.6b0752510.1021/acsnano.6b07525 ↗
3. 10.1002/adfm.20150489910.1002/adfm.201504899 ↗
4. 10.1038/nrd261410.1038/nrd2614 ↗
5. 10.1016/j.yexmp.2008.12.00410.1016/j.yexmp.2008.12.004 ↗
6. 10.18632/oncotarget.1053710.18632/oncotarget.10537 ↗
7. 10.1038/509S58a10.1038/509S58a ↗
8. 10.1002/jgm.269810.1002/jgm.2698 ↗
9. 10.1016/j.gene.2013.03.13710.1016/j.gene.2013.03.137 ↗
10. 10.1002/med.2009010.1002/med.20090 ↗
11. 10.1073/pnas.93.22.1234910.1073/pnas.93.22.12349 ↗
12. 10.1074/jbc.273.40.2616410.1074/jbc.273.40.26164 ↗
13. 10.1038/nrd274210.1038/nrd2742 ↗
14. 10.1016/j.plipres.2008.03.00210.1016/j.plipres.2008.03.002 ↗
15. 10.1038/nrg376310.1038/nrg3763 ↗
16. 10.1089/10430340175014866710.1089/104303401750148667 ↗
17. 10.1371/journal.pone.003483310.1371/journal.pone.0034833 ↗
18. 10.1158/2159-8290.CD-12-042910.1158/2159-8290.CD-12-0429 ↗
19. 10.1016/j.biomaterials.2014.03.01710.1016/j.biomaterials.2014.03.017 ↗
20. 10.1016/j.tibtech.2013.09.00710.1016/j.tibtech.2013.09.007 ↗
21. 10.1016/S0163-7827(03)00032-810.1016/S0163-7827(03)00032-8 ↗
22. 10.1038/cr.2015.910.1038/cr.2015.9 ↗
23. 10.1021/bk-2006-0934.ch01610.1021/bk-2006-0934.ch016 ↗
24. 10.1016/j.biomaterials.2004.07.01810.1016/j.biomaterials.2004.07.018 ↗
25. 10.1073/pnas.053029110010.1073/pnas.0530291100 ↗
26. 10.1158/0008-5472.CAN-05-201810.1158/0008-5472.CAN-05-2018 ↗
27. 10.1158/0008-5472.CAN-06-203010.1158/0008-5472.CAN-06-2030 ↗
28. 10.1021/bc500431310.1021/bc5004313 ↗
29. Eliaz R. E. · Cancer Res. · 2001 · 61 · 2592
30. 10.1166/jbn.2015.213610.1166/jbn.2015.2136 ↗
31. 10.1016/j.jconrel.2013.10.01510.1016/j.jconrel.2013.10.015 ↗
32. 10.1002/jps.2220010.1002/jps.22200 ↗
33. 10.1186/1465-9921-6-14710.1186/1465-9921-6-147 ↗
34. 10.1038/3501959610.1038/35019596 ↗
35. 10.1016/S0005-2736(97)00110-710.1016/S0005-2736(97)00110-7 ↗
36. 10.1038/nm.318910.1038/nm.3189 ↗
37. 10.1038/nature0878010.1038/nature08780 ↗
38. 10.1016/j.jconrel.2007.10.02410.1016/j.jconrel.2007.10.024 ↗
39. 10.1038/sj.gt.330086510.1038/sj.gt.3300865 ↗
40. 10.1073/pnas.98.2.63510.1073/pnas.98.2.635 ↗
41. 10.1172/JCI20011298310.1172/JCI200112983 ↗
42. 10.1016/j.addr.2012.09.03710.1016/j.addr.2012.09.037 ↗
43. 10.1021/acsami.6b1014610.1021/acsami.6b10146 ↗
44. 10.1021/am200358p10.1021/am200358p ↗
45. 10.1021/acsami.5b0655210.1021/acsami.5b06552 ↗
46. 10.1021/nn204102q10.1021/nn204102q ↗
47. 10.1021/acsami.5b1161910.1021/acsami.5b11619 ↗
48. 10.1016/j.addr.2015.12.00210.1016/j.addr.2015.12.002 ↗
49. 10.1038/nnano.2013.18110.1038/nnano.2013.181 ↗